ArkBio Receives FDA Clearance for Phase 2 Trial of Novel Anti-Fibrotic Drug AK3280 in Idiopathic Pulmonary Fibrosis
核心洞察
Shanghai Ark Biopharmaceutical received FDA clearance for its Investigational New Drug application for AK3280, enabling a Phase 2 proof-of-concept trial in idiopathic pulmonary fibrosis (搜索) patients.
The multi-center, randomized, partially double-blind trial will evaluate the efficacy, safety, and pharmacokinetics of oral AK3280 compared to placebo and active controls.
Previous Phase 2 results in China showed AK3280 demonstrated statistically significant, dose-dependent improvements in forced vital capacity at Week 24 with favorable safety profile.
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio (搜索)) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for AK3280, a novel anti-fibrotic therapy for idiopathic pulmonary fibrosis (搜索) (IPF (搜索)). The clearance enables the company to initiate a Phase 2 proof-of-concept clinical trial in the United States, representing a significant milestone in the global clinical development of this experimental treatment.
Phase 2 Trial Design and Objectives
The upcoming Phase 2 study is designed as a multi-center, randomized, partially double-blind, placebo- and active-controlled trial. The study will evaluate the efficacy, safety, and pharmacokinetics of oral AK3280 in patients with IPF (搜索). This international Phase 2 proof-of-concept trial is expected to generate critical clinical data to support future regulatory submissions and potential commercialization in the United States and other major markets.
Addressing Critical Unmet Medical Need
IPF (搜索) represents a progressive, irreversible, and ultimately fatal interstitial lung disease (搜索) characterized by fibrotic remodeling of lung tissue that leads to respiratory failure (搜索). The median survival following diagnosis is approximately 2-5 years, highlighting the urgent need for effective treatments.
Currently approved therapies, including pirfenidone, nintedanib, and nerandomilast, can slow disease progression but their clinical benefit remains limited. These treatments are frequently associated with gastrointestinal adverse events such as diarrhea and nausea, creating tolerability challenges that contribute to poor long-term adherence in a substantial proportion of patients. This situation creates a significant unmet need for therapies that provide improved efficacy with enhanced safety and tolerability profiles.
Promising Phase 2 Results from China
AK3280 is characterized as an optimized, small-molecule, broad-spectrum anti-fibrotic agent. In a Phase 2 proof-of-concept study conducted in China, AK3280 demonstrated encouraging clinical activity, including a statistically significant, dose-dependent absolute increase from baseline in forced vital capacity (FVC) at Week 24. Improvements were also observed across additional lung function parameters, suggesting meaningful clinical benefit.
Importantly, AK3280 exhibited a favorable safety and tolerability profile in the Chinese study, with no apparent increase in the gastrointestinal adverse effects commonly associated with currently available IPF (搜索) therapies. This safety profile could potentially address one of the key limitations of existing treatments.
Company Background and Pipeline
ArkBio (搜索) is a commercial-stage biotechnology company focused on the discovery and development of innovative therapeutics for respiratory and pediatric diseases. Founded in 2014, the company has established proprietary technology platforms and a differentiated research and development pipeline through internal innovation and strategic collaborations.
The company's key pipeline assets include Ziresovir (AK0529), described as the first direct-acting antiviral for RSV with positive pivotal Phase 3 results, and AK0901, which is approved in China for the treatment of ADHD (搜索) and currently commercialized. AK3280 is positioned as a potentially best-in-class anti-fibrotic agent based on its positive Phase 2 results in idiopathic pulmonary fibrosis (搜索).
ArkBio (搜索) has established strategic partnerships with multinational pharmaceutical companies and leading academic institutions, including Roche, Genentech, The Scripps Research Institute, and the Institute of Microbiology of the Chinese Academy of Sciences (搜索), as well as domestic and international biotech companies and venture capital partners.